# Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma

> **NCT04296461** · PHASE1 · UNKNOWN · sponsor: **UWELL Biopharma** · enrollment: 20 (estimated)

## Conditions studied

- B-cell Non-Hodgkin Lymphoma

## Interventions

- **GENETIC:** Welgenaleucel

## Key facts

- **NCT ID:** NCT04296461
- **Lead sponsor:** UWELL Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-27
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04296461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04296461, "Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04296461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*